SUMMIT肺癌筛查队列中基于症状与肺功能检测慢阻肺
气流阻塞为基线低剂量CT肺癌风险的独立危险因素,未诊断慢阻肺者风险尤其高。
要点
- 肺癌筛查队列中近1/5存在未诊断的 symptomatic COPD。
- 未诊断慢阻肺患者肺功能损害和症状负担较已诊断者轻。
- 气流阻塞是肺癌风险的独立危险因素,未诊断慢阻肺者风险更高。
核心结论
- 在肺癌筛查中靶向病例发现可检出高比例未诊断的症状性慢阻肺
- 未诊断慢阻肺个体肺癌风险高
研究设计与样本
- 所有参与者接受呼吸咨询和肺功能检测,高风险者行基线低剂量CT
主要发现
- 19.7%符合未诊断慢阻肺标准
- 未诊断者较已诊断者更多为男性(59.1% vs 53.2%,p<0.001)、当前吸烟(54.9% vs 47.6%,p<0.001)和少数族裔(p<0.001)
- 未诊断者GOLD 1-2级比例更高(85.3% vs 68.4%,p<0.001),GOLD A-B组比例更高(95.6% vs 77.9%,p<0.001)
- 气流阻塞为基线LDCT肺癌风险的独立危险因素(调整OR 2.74,95%CI 1.73-4.34;p<0.001)
- 未诊断慢阻肺者肺癌风险调整OR 2.79(95%CI 1.67-4.64;p<0.001)
临床怎么用
- 在肺癌筛查队列中结合症状评估与肺功能检测可发现未诊断慢阻肺
- 未诊断慢阻肺者应视为肺癌高风险人群
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COPD is a major comorbidity in lung cancer screening (LCS) cohorts, with a high prevalence of undiagnosed COPD. Combining symptom assessment with spirometry in this setting may enable earlier diagnosis of clinically significant COPD and facilitate increased understanding of lung cancer risk in COPD. In this study, we wished to understand the prevalence, severity, clinical phenotype and lung cancer risk of individuals with symptomatic undiagnosed COPD in a LCS cohort. METHODS: 16 010 current or former smokers aged 55-77 years attended a lung health check as part of the SUMMIT Study. A respiratory consultation and spirometry were performed alongside LCS eligibility assessment. Those with symptoms, no previous COPD diagnosis and airflow obstruction were labelled as undiagnosed COPD. Baseline low-dose computed tomography (LDCT) was performed in those at high risk of lung cancer (PLCOm2012 score ≥1.3% and/or meeting USPSTF 2013 criteria). RESULTS: Nearly one in five (19.7%) met criteria for undiagnosed COPD. Compared with those previously diagnosed, those undiagnosed were more likely to be male (59.1% versus 53.2%; p<0.001), currently smoking (54.9% versus 47.6%; p<0.001) and from an ethnic minority group (p<0.001). Undiagnosed COPD was associated with less forced expiratory volume in 1 s impairment (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 and 2: 85.3% versus 68.4%; p<0.001) and lower symptom/exacerbation burden (GOLD A and B groups: 95.6% versus 77.9%; p<0.001) than those with known COPD. Multivariate analysis demonstrated that airflow obstruction was an independent risk factor for lung cancer risk on baseline LDCT (adjusted OR 2.74, 95% CI 1.73-4.34; p<0.001), with a high risk seen in those with undiagnosed COPD (adjusted OR 2.79, 95% CI 1.67-4.64; p<0.001). CONCLUSIONS: Targeted case-finding within LCS detects high rates of undiagnosed symptomatic COPD in those most at risk. Individuals with undiagnosed COPD are at high risk for lung cancer.
引用
- Tisi, Dickson, Horst, et al. Detection of COPD in the SUMMIT Study lung cancer screening cohort using symptoms and spirometry. Eur Respir J. 2022. PMID: 35896207. doi:10.1183/13993003.00795-2022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。